Enhanced Stability of Long-Living Immobilized Recombinant β-d-N-Acetyl-Hexosaminidase A on Polylactic Acid (PLA) Films for Potential Biomedical Applications
Source abstract
Abstract
β-d-N-acetyl-hexosaminidase (Hex, EC 3.2.1.52) is an acid hydrolase that catalyzes the cleavage of the β-1,4 bond in N-acetyl-d-galactosamine (Gal-NAc) and N-acetyl-d-glucosamine (Glc-NAc) from the non-reducing end of oligosaccharides and glycoconjugates. It is widely expressed in both the prokaryotic and eukaryotic world, where it performs multiple and important functions. Hex has antifungal activity in plants, is capable of degrading many biological substrates, and can play an important role in the biomedical field for the treatment of Tay-Sachs and Sandhoff diseases. With the aim being able to obtain a device with a stable enzyme, a method of covalent immobilization on polylactic acid (PLA) films was developed for the A isoform of the β-d-N-acetyl-hexosaminidase enzyme (HexA), produced in a recombinant way from Human Embryonic Kidney-293 (HEK-293) cells and suitably purified. An in-depth biochemical characterization of the immobilized enzyme was carried out, evaluating the optimal temperature, thermal stability, pH parameters, and Km value. Moreover, the stability of the enzymatic activity over time was assessed. The results obtained showed an improvement in terms of kinetic parameters and stability to heat for the enzyme following immobilization and the presence of HexA in two distinct immobilized forms, with an unexpected ability for one of them to maintain its functionality for a long period of time (over a year). The stability and functionality of the enzyme in its immobilized form are therefore extremely promising for potential biotechnological and biomedical applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Carbohydrate Chemistry and Synthesis · Enzyme Catalysis and Immobilization · Lysosomal Storage Disorders Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
Center of Excellence on Innovative Nanostructured Materials—CEMIN, University of Perugia, 06123 Perugia, Italy
Department of Physics and Geology, University of Perugia, 06123 Perugia, Italy
References (65)
Show source-provided references
1. Natural history and inherited disorders of a lysosomal enzyme, beta-hexosaminidase10.1016/S0021-9258(18)60406-5 ↗
2. Selective β-N-acetylhexosaminidase from Aspergillus versicolor—A tool for producing bioactive carbohydrates10.1007/s00253-018-9534-z ↗
3. β-N-acetylhexosaminidase: What’s in a name…?10.1016/j.biotechadv.2010.04.004 ↗
4. The chitin catabolic cascade in the marine bacterium Vibrio furnissii: Molecular cloning, isolation, and characterization of a periplasmic chitodextrinase10.1074/jbc.271.52.33414 ↗
5. The β-N-acetylhexosaminidase of Entamoeba histolytica is composed of two homologous chains and has been localized to cytoplasmic granules10.1016/j.molbiopara.2004.09.003 ↗
6. Gooday, G.W. (1994). Physiology of microbial degradation of chitin and chitosan. Biochemistry of Microbial Degradation, Springer.10.1007/978-94-011-1687-9_9 ↗
7. Role for lysosomal enzyme β-hexosaminidase in the control of mycobacteria infection10.1073/pnas.0708110105 ↗
8. Microbial β-N-acetylhexosaminidases and their biotechnological applications10.1016/S0141-0229(98)00171-9 ↗
9. Plant chitinases are potent inhibitors of fungal growth10.1038/324365a0 ↗
10. Backbone structures in human milk oligosaccharides: Trans-glycosylation by metagenomic β-N-acetylhexosaminidases10.1007/s00253-015-6550-0 ↗
11. Visnapuu, T., Teze, D., Kjeldsen, C., Lie, A., Duus, J.Ø., André-Miral, C., Pedersen, L.H., Stougaard, P., and Svensson, B. (2020). Identification and Characterization of a β-N-Acetylhexosaminidase with a Biosynthetic Activity from the Marine Bacterium Paraglaciecola hydrolytica S66T. Int. J. Mol. Sci., 21.10.3390/ijms21020417 ↗
12. Lysosomal storage diseases
13. An enzyme with properties similar to those of β-N-acetylhexosaminidase S is expressed in the promyelocytic cell line HL-6010.1042/bj2670111 ↗
14. Particular forms of β-N-acetylhexosaminidase in human leukaemic cells10.1016/0020-711X(92)90324-T ↗
15. Ikonne, J.U., Rattazzi, M.C., and Desnick, R.J. (1975). Characterization of Hex S, the major residual beta hexosaminidase activity in type O Gm2 gangliosidosis (Sandhoff-Jatzkewitz disease). Am. J. Hum. Genet., 27.
16. Deficient hexosaminidase activity in an exceptional case of Tay-Sachs disease with additional storage of kidney globoside in visceral organs10.1016/0024-3205(68)90024-6 ↗
17. Translation initiation in the HEXB gene encoding the beta-subunit of human beta-hexosaminidase10.1016/S0021-9258(17)45286-0 ↗
18. Crystallographic structure of human β-hexosaminidase A: Interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis10.1016/j.jmb.2006.04.004 ↗
19. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease10.1093/hmg/ddi216 ↗
20. Effective gene therapy in an authentic model of Tay-Sachs-related diseases10.1073/pnas.0603765103 ↗
21. Solovyeva, V.V., Shaimardanova, A.A., Chulpanova, D.S., Kitaeva, K.V., Chakrabarti, L., and Rizvanov, A.A. (2018). New Approaches to Tay-Sachs Disease Therapy. Front. Physiol., 9.10.3389/fphys.2018.01663 ↗
22. New therapeutic options for lysosomal storage disorders: Enzyme replacement, small molecules and gene therapy10.1007/s00439-006-0280-4 ↗
23. Futerman, A.H., and Van Meer, G. (2004). The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol., 5.10.1038/nrm1423 ↗
24. Newborn screening for lysosomal storage disorders10.1053/j.semperi.2015.03.005 ↗
25. Clinical characteristics of early juvenile GM2 gangliosidosis: A case report
26. Lysosomal storage disorders: The cellular impact of lysosomal dysfunction10.1083/jcb.201208152 ↗
27. The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy
28. Recent developments in therapeutic approaches for lysosomal storage diseases10.2174/157488911794079127 ↗
29. Gangliosides and gangliosidoses: Principles of molecular and metabolic pathogenesis10.1523/JNEUROSCI.0822-13.2013 ↗
30. Prediction of neuropathology in mucopolysaccharidosis I patients10.1016/j.ymgme.2004.09.004 ↗
31. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives10.1016/j.addr.2017.05.004 ↗
32. Treatment strategies for lysosomal storage disorders10.1111/dmcn.13600 ↗
33. Storage solutions: Treating lysosomal disorders of the brain10.1038/nrn1725 ↗
34. Lending a helping hand, screening chemical libraries for compounds that enhance β-hexosaminidase A activity in GM2 gangliosidosis cells10.1111/j.1742-4658.2007.06040.x ↗
35. Production of human β-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene10.1093/glycob/cwp080 ↗
36. Enzyme replacement therapy: A review and its role in treating lysosomal storage diseases10.3928/19382359-20180424-01 ↗
37. Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI
38. Limitations of enzyme replacement therapy: Current and future10.1007/s10545-006-0239-6 ↗
39. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., and Emiliani, C. (2019). Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. J. Funct. Biomater., 10.10.3390/jfb10010004 ↗
40. Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders10.1007/s13346-012-0072-4 ↗
41. Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A10.1016/j.jconrel.2017.02.016 ↗
42. Enzyme immobilization: An overview on techniques and support materials10.1007/s13205-012-0071-7 ↗
43. Potential of different enzyme immobilization strategies to improve enzyme performance10.1002/adsc.201100163 ↗
44. Enzyme immobilization: An update10.1007/s12154-013-0102-9 ↗
45. Romero-Fernández, M., and Paradisi, F. (2020). General Overview on Immobilization Techniques of Enzymes for Biocatalysis. Catal. Immobil. Methods Appl., 409–435.10.1002/9783527817290.ch12 ↗
46. Zdarta, J., Meyer, A.S., Jesionowski, T., and Pinelo, M. (2018). A general overview of support materials for enzyme immobilization: Characteristics, properties, practical utility. Catalysts, 8.10.3390/catal8020092 ↗
47. Chapman, J., Ismail, A., and Dinu, C. (2018). Industrial applications of enzymes: Recent advances, techniques, and outlooks. Catalysts, 8.10.3390/catal8060238 ↗
48. Evaluation of immobilized enzymes for industrial applications10.1039/c3cs35511j ↗
49. Enzymes and bioconversions of industrial, pharmaceutical, and biotechnological significance10.1021/op100302x ↗
50. Polchi, A., Magini, A., Mazuryk, J., Tancini, B., Gapiński, J., Patkowski, A., Giovagnoli, S., and Emiliani, C. (2016). Rapamycin loaded solid lipid nanoparticles as a new tool to deliver mTOR inhibitors: Formulation and in vitro characterization. Nanomaterials, 6.10.3390/nano6050087 ↗
51. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases10.1080/17425247.2016.1178237 ↗
52. Pharmacokinetics and biodistribution of surface modification polymeric nanoparticles10.1007/s12272-001-1191-8 ↗
53. The effect of nanoparticle size on the probability to cross the blood-brain barrier: An in-vitro endothelial cell model10.1186/s12951-015-0075-7 ↗
54. The effect of nanoparticle size on the ability to cross the blood–brain barrier: An in vivo study10.2217/nnm-2017-0022 ↗
55. Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems10.1016/j.cej.2018.01.010 ↗
56. Industrial use of immobilized enzymes10.1039/c3cs35506c ↗
57. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding10.1016/0003-2697(76)90527-3 ↗
58. Emiliani, C., Beccari, T., Stirling, J.L., Sciarra, R., and Orlacchio, A. (1987). New Biospecific Chromatographies of β-Hexosaminidases. Macromolecular Biorecognition, Humana Press.10.1007/978-1-4612-4600-8_27 ↗
59. Robinson, D., and Stirling, J.L. (1968). N-acetyl-β-glucosaminidases in human spleen. Biochem. J., 107.10.1042/bj1070321 ↗
60. LaemmLi, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227.10.1038/227680a0 ↗
61. Calzoni, E., Cesaretti, A., Tacchi, S., Caponi, S., Pellegrino, R.M., Luzi, F., Cottone, F., Fioretto, D., Emiliani, C., and Di Michele, A. (2021). Covalent Immobilization of Proteases on Polylactic Acid for Proteins Hydrolysis and Waste Biomass Protein Content Valorization. Catalysts, 11.10.3390/catal11020167 ↗
62. β-Hexosaminidase over-expression affects lysosomal glycohydrolases expression and glycosphingolipid metabolism in mammalian cells10.1007/s11010-011-1163-0 ↗
63. Characterization of recombinant human lysosomal beta-hexosaminidases produced in the methylotrophic yeast Pichia pastoris10.11144/Javeriana.SC21-3.corh ↗
64. Liberation of N-acetylglucosamine-6-sulfate by human beta-N-acetylhexosaminidase A10.1016/S0021-9258(18)42985-7 ↗
65. Purification and characterization of β-N-acetylhexosaminidase I2 from human liver10.1042/bj2340157 ↗